Catalog No.
Product Name
Application
Product Information
Citations
-
Antibody-Drug Conjugate
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). This reagent exhibits potent antitumor activity and is valuable for research applications involving glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue. Its mechanism of action combines selective targeting of EGFR with cytotoxic delivery, making it a significant tool in cancer research and therapeutic studies. -
Antibody-Drug Conjugates
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate that targets HER2, featuring a potent payload linked to a STING agonist. This innovative design promotes immune activation, enhancing anticancer efficacy. Its applications are particularly relevant in the development of targeted therapies for HER2-positive cancers, making it a valuable tool for cancer research. -
Antibody-drug Conjugate
Trastuzumab emtansine is an antibody-drug conjugate (ADC) that combines the HER2-targeting capabilities of trastuzumab with the cytotoxic effects of the microtubule-inhibitory agent DM1. This compound demonstrates potent antitumor activity and is particularly relevant in the study of advanced breast cancer. Its dual mechanism allows for targeted delivery of cytotoxic agents, making it a valuable tool in oncological research and therapeutic development. -
Antibody-Drug Conjugate
Disitamab vedotin is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). This reagent consists of a monoclonal antibody linked through a cleavable connector to the cytotoxic drug Monomethyl auristatin E (MMAE). Disitamab vedotin is designed to enhance antitumor immunity and is applicable in cancer research, particularly in studies focused on HER2-positive malignancies. -
Drug-Linker Conjugate for ADC
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a linker alongside the potent cytotoxic agent MMAE, enabling targeted delivery to cells expressing the c-Kit receptor. This compound can facilitate the synthesis of NN3201 by conjugating with NN2101 (anti c-Kit), which promotes rapid internalization and effectively disrupts SCF-driven signaling pathways. Consequently, NN3201 demonstrates significant anti-tumor activity in various cancer models, including small cell lung cancer (SCLC) and gastrointestinal stromal tumors (GIST). -
Antibody-Drug Conjugate
Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting the cluster of differentiation 19 (CD19) antigen. This compound comprises the Loncastuximab antibody linked to Tesirine, a potent cytotoxic agent. Upon binding to CD19, Loncastuximab tesirine is internalized, leading to apoptosis in malignant B-cells. This reagent is primarily utilized in research focused on diffuse large B-cell lymphoma and related hematological malignancies. -
ADC Cytotoxin
Mytoxin B is an ADC cytotoxin that functions as a satratoxin-type trichothecene macrolide. It is known for inducing cell apoptosis primarily through the PI3K/Akt signaling pathway. This compound is utilized in research applications focused on targeted cancer therapies and the study of apoptosis mechanisms in various cell types. -
Drug-Linker Conjugates for ADC
Mal-N(Me)-C6-N(Me)-PNU-159682 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound utilizes the Mal-N(Me)-C6-N(Me) linker to selectively deliver the cytotoxic agent PNU-159682 to CD46-expressing cells. Upon entering these cells, the linker is cleaved by cathepsin B, resulting in the release of PNU-159682, which induces DNA damage and apoptosis. Notably, Mal-N(Me)-C6-N(Me)-PNU-159682 demonstrates significant tumor regression in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). -
Antibody-drug Conjugate
HE-S2 is an antibody-drug conjugate that targets the PD-1/PD-L1 interaction, thereby enhancing antitumor immune responses. By activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway, HE-S2 exhibits significant antitumor activity. This reagent is suitable for research applications involving cancer immunotherapy and the modulation of immune responses in tumor microenvironments. -
ADC Cytotoxin
γ-Amanitin is a potent ADC cytotoxin derived from the Amanita mushroom, specifically targeting RNA polymerase II to inhibit mRNA synthesis. This compound exhibits high toxicity across various cell types, making it a valuable tool in cancer research and therapeutic applications. γ-Amanitin competes effectively with monoclonal antibodies, displaying an IC50 value of 163.1 ng/mL. Its ability to disrupt transcriptional processes positions it as a key reagent in studies focused on gene expression and cellular response mechanisms. -
Drug-linker Conjugates for ADC
MC-VC-PAB-Cyclohexanediamine-Thailanstatin A functions as a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. This compound combines the potent cytotoxic properties of Thailanstatin A with a cleavable linker (MC-vc-PAB), facilitating targeted delivery and release of the drug within cancer cells. It is suitable for ADC synthesis and can be utilized in research focused on targeted cancer therapies and improved therapeutic index. -
Drug-Linker Conjugates for ADC
Tesirine is a pyrrolobenzodiazepine (PBD) dimer used as a payload in antibody-drug conjugates (ADCs), primarily targeting cancer cells. It exhibits remarkable antitumor efficacy through its ability to cross-link DNA at the minor groove, leading to potent cytotoxic effects. Tesirine’s favorable hydrophobicity and improved conjugation properties make it an effective component for developing targeted cancer therapies. Its released warhead, SG3199, demonstrates picomolar activity across various cancer cell lines, highlighting its potential in cancer research and therapeutic applications. -
ADC Linker
BS2G Crosslinker Disodium is an amine-reactive homobifunctional crosslinker that targets amine groups on proteins and peptides. This reagent facilitates the stable conjugation of proteins, peptides, and biomolecules, making it valuable in the development of antibody-drug conjugates (ADCs). Its application extends to various biochemical research and therapeutic studies, where precise linkage is essential for functionality. -
Drug-Linker Conjugate for ADC
DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a SG3199-based DNA small channel crosslinker combined with a cleavable linker, facilitating targeted delivery of therapeutic agents. This reagent is suitable for the synthesis of ADCs, enabling enhanced efficacy in drug-based cancer therapies and other biomedical research applications. -
ADC Payload
Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid is a cytotoxic pyrrolobenzodiazepine (PBD) dimer derivative designed for use as an antibody-drug conjugate (ADC) payload. This compound exhibits moderate DNA alkylating activity, contributing to its potent cytotoxic effects on target cells. It is primarily utilized in research applications focused on developing targeted cancer therapies through antigen-dependent cytotoxicity mechanisms. -
ADC Payload
(S,S)-D211 is a stereoisomer of D211 that functions as a potent ADC payload through its DNA-damaging activity. As a member of the PBD dimer family, (S,S)-D211 is designed for incorporation into antibody-drug conjugates (ADCs), enhancing their cytotoxic efficacy in targeted cancer therapies. Its ability to induce DNA damage makes it a valuable tool for research in the development of innovative cancer treatments. -
Drug-Linker Conjugate for ADC
Puxitatug samrotecan drug-linker is a highly specialized drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound combines a potent topoisomerase I inhibitor with a linker moiety, facilitating the targeted delivery of cytotoxic agents to neoplastic cells. Puxitatug samrotecan drug-linker enables the synthesis of ADCs such as Puxitatug samrotecan, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. This reagent is essential for researchers focusing on innovative cancer therapies and targeted drug delivery systems. -
Drug-Linker Conjugates For ADC
Vat-Cit-PAB-Monomethyl Dolastatin 10 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It utilizes Monomethyl Dolastatin 10, a highly effective tubulin inhibitor, linked through the Vat-Cit-PAB linker to enhance its therapeutic potential. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research and the development of targeted therapies. -
Drug-Linker Conjugates for ADC
ST8155AA1 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) with a mechanism targeting histone deacetylases (HDACs). This compound exhibits significant antitumor activity, making it a valuable tool for cancer research, particularly in the development of targeted therapies. Its application in ADCs enhances the specificity and efficacy of therapeutic agents against tumor cells. -
Drug-Linker Conjugates for ADC
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a peptide-cleavable drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The maytansinoid moiety (DM) enhances cytotoxicity, making this conjugate an effective tool for targeted cancer therapy. Its unique chemical structure allows for precise release of the therapeutic agent in the tumor microenvironment, facilitating specific delivery and reduced systemic toxicity. This reagent is suitable for research focusing on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Mal-VC-PAB-ABAEP-Azonafide is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. It combines the potent cytotoxic effects of Azonafide with the Mal-VC-PAB linker to enhance targeted delivery and efficacy against tumor cells. This reagent is utilized in research focusing on advanced therapeutic strategies for cancer treatment, specifically in the development of ADCs that aim to improve therapeutic selectivity while minimizing systemic toxicity. -
Drug-Linker Conjugate For ADC
Val-Cit-PAB-MMAF is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound integrates a peptide linker, Val-Cit-PAB, with MMAF, a highly effective inhibitor of tubulin polymerization. Val-Cit-PAB-MMAF is utilized in research focusing on targeted cancer therapies, enhancing the specificity and efficacy of ADCs through selective delivery mechanisms. -
Drug-Linker Conjugates for ADC
Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan serves as a potent drug-linker conjugate for antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while reducing off-target effects. It is particularly valuable in the development of innovative cancer treatments, enabling precise targeting and improved pharmacokinetic profiles. -
Drug-Linker Conjugate for ADC
TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a topoisomerase 1 inhibitor and a cleavable linker, facilitating controlled release of the active drug upon target interaction. It is suitable for the synthesis of ADCs aimed at enhancing the specificity and efficacy of therapeutic agents in cancer research and treatment. -
Drug-linker Conjugate For ADC
MC-Gly-Gly-Phe-Exatecan analog 38 is a linker compound designed for use in antibody-drug conjugates (ADCs). This synthetic analog facilitates the delivery of cytotoxic agents to targeted cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It serves as a valuable tool in cancer research for the development and synthesis of various ADCs. -
Drug-Linker Conjugates for ADC
GDP-Fuc-AM-VcPAB-MMAE is a conjugate of the cytotoxic agent Monomethyl auristatin E (MMAE) linked via a specific linker system. This precursor molecule plays a critical role in the development of antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutics in cancer research. Its utilization in experimental studies aids in the exploration of ADC efficacy and potential treatment pathways for neoplastic diseases. -
Drug-Linker Conjugate for ADC
Ledadotin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises Auristatin F-hydroxypropylamide, a microtubule inhibitor, linked to a specialized PEG-based linker. This compound is utilized in the synthesis of the ADC Emiltatug ledadotin, making it valuable for targeted cancer therapies and related research applications. -
Drug-Linker Conjugates for ADC
DM21-L-G is a drug-linker conjugate designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to targeted cells, enhancing therapeutic efficacy while minimizing off-target effects. Its application is critical in the development of targeted cancer therapies, enabling researchers to explore new avenues in precision medicine. -
Drug-Linker Conjugates for ADC
Amidate-VC-PAB-MMAF is a cleavable drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines the Amidate-VC-PAB linker with MMAF, a potent inhibitor of tubulin polymerization, to enhance the targeted delivery of therapeutic agents. By utilizing this linker, researchers can minimize off-target cytotoxicity while improving the efficacy of ADCs in cancer treatments and other applications in drug development. -
Drug-Linker Conjugates for ADC
PNU-EDA-Gly5 is an oligo-glycine linker designed for antibody-drug conjugate (ADC) synthesis, consisting of the DNA topoisomerase I inhibitor PNU-159682 linked to EDA-Gly5. This compound facilitates targeted delivery of cytotoxic agents while maintaining the activity of the payload, making it useful for the development of ADCs aimed at cancer therapies. Researchers can utilize PNU-EDA-Gly5 to explore novel therapeutic strategies in oncology and enhance the efficacy of targeted treatment modalities. -
Drug-Linker Conjugate for ADC
APL-1092 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent payload Exatecan. The structure incorporates a stable linker to facilitate precise delivery of the cytotoxic agent to targeted cells. APL-1092 is intended for research into targeted cancer therapies, offering a promising tool for studying the efficacy and mechanism of ADCs in various tumor models. -
Drug-Linker Conjugates for ADC
MB-VC-MGBA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a potent antitumor activity mechanism. This compound employs MGBA, a minor-groove-binding DNA-alkylating agent, connected through the linker MB-VC, providing effective targeted delivery in cancer therapy research. Its unique design facilitates precise targeting and enhances therapeutic efficacy for various malignancies. -
Drug-Linker Conjugates for ADC
Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a unique ADC linker (Mc-Lys(PEG12)-Cap-Ala-Ala-PABC) combined with the potent DNA topoisomerase I inhibitor, Exatecan. It is particularly relevant for the development of targeted therapies against HER2-positive breast cancer, facilitating the selective delivery of cytotoxic agents to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
XB010 drug-linker is a conjugate that combines MMAE with RED-601, specifically designed for the synthesis of antibody-drug conjugates (ADCs). This drug-linker facilitates targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Researchers utilize XB010 for the development of ADCs aimed at improving anticancer treatments and studying the mechanisms of drug action in tumor biology. -
Drug-Linker Conjugates for ADC
DBA-DM4 is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. It combines the potent tubulin inhibitor DM1 with the SPDP linker to facilitate targeted delivery of cytotoxic agents to cancer cells. DBA-DM4 is utilized in research aimed at enhancing the efficacy and selectivity of therapeutic antibodies in oncology, making it a valuable tool for the development of novel cancer treatments. -
Drug-Linker Conjugate for ADC
Mal-PEG8-Phe-Lys-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a degradable linker composed of Mal-PEG8-Phe-Lys-PAB, covalently linked to the potent cytotoxic agent Exatecan. It is utilized in research focusing on targeted cancer therapies, enabling the effective delivery of cytotoxic agents to cancer cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
N-(Hexanoyloxy)succinimide-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It features a hexanoyloxy group and a degradable PEG linker, which facilitates the delivery of the cytotoxic agent MMAE to target cells. This compound shows significant antitumor activity and is useful in the development of targeted cancer therapies, enhancing the efficacy of ADCs by minimizing off-target effects. -
Drug-linker Conjugate for ADC
Rha-PEG3-SMCC is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. Featuring a noncleavable linker, Rha-PEG3 enhances the stability and efficacy of the conjugate while the SMCC protein crosslinker facilitates the attachment to monoclonal antibodies. This compound exhibits potent antitumor activity, making it suitable for cancer research and the development of targeted therapies. -
Drug-Linker Conjugates for ADC
Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of the payload MMAE and the linker Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB, enabling effective targeted delivery of cytotoxic agents to cancer cells. The conjugate functions by utilizing the specificity of antibodies to selectively deliver the cytotoxic MMAE, facilitating enhanced therapeutic efficacy in oncological research. -
Drug-Linker Conjugate for ADC
STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound functions by targeting the STING pathway, enhancing immune responses against tumors. It is ideal for ADC synthesis, featuring a target protein ligand, E3 ligase ligand, and a flexible linker structure, facilitating efficient delivery of cytotoxic agents to cancer cells. -
Drug-Linker Conjugates for ADC
Deruxtecan analog 2 monoTFA is a derivative of Deruxtecan and serves as a drug-linker conjugate for antibody-drug conjugates (ADCs). This compound features the DX-8951 derivative (Dxd) linked through a specialized ADC linker, enabling targeted delivery of cytotoxic agents to cancer cells. It is utilized in research focused on the development of ADCs for improved therapeutic efficacy in oncology. -
Drug-Linker Conjugate for ADC
Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound integrates a potent tubulin inhibitor, MMAE, with a stable linker (Mal-Val-Lys-PAB), enabling targeted delivery of chemotherapeutic agents. Mal-Val-Lys-PAB-MMAE is suitable for the synthesis of ADCs, facilitating research in cancer therapeutics and enhancing the efficacy of targeted therapies. -
Drug-Linker Conjugates for ADC
Aminooxy CatB-LXR is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It serves as a targeted delivery system that facilitates the coupling of therapeutic agents to antibodies, enhancing cytotoxicity specifically in cancer cells. This compound is instrumental in advancing research in ADC development, potentially improving therapeutic outcomes in oncology. -
Drug-Linker Conjugates for ADC
SDP-LIV1 drug-linker is a conjugate designed for antibody-drug conjugates (ADCs) that combines a potent topoisomerase I inhibitor with a specialized linker. This compound facilitates targeted drug delivery to cancer cells, enhancing the therapeutic efficacy of ADCs while minimizing systemic toxicity. SDP-LIV1 is suitable for research applications aimed at the development and optimization of ADC formulations in cancer therapeutics. -
Drug-Linker Conjugate for ADC
Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7 functions as a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound integrates a potent NMT inhibitor with a stable and cleavable linker, facilitating targeted delivery of therapeutic agents. It is suitable for the synthesis and development of ADCs aimed at enhancing therapeutic efficacy in various cancer research applications. -
Drug-Linker Conjugates for ADC
m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates targeted delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. It combines a polyethylene glycol (PEG) spacer with a maleimide reactive group, allowing for efficient conjugation to antibodies, making it valuable for researchers developing novel ADCs for targeted cancer therapies. -
Drug-Linker Conjugates for ADC
Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 serves as a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound integrates the ADC linker Mal-Phe-C4-VC-PAB with the potent cytotoxin DMEA-PNU-159682, which is derived from the metabolite profile of nemorubicin (MMDX) due to liver microsomal processing. Its primary biological activity involves targeted cytotoxicity to cancer cells, making it a valuable tool for research in cancer therapeutics and drug delivery systems. -
Drug-Linker Conjugates for ADC
Maytansine derivative M24 is a potent drug-linker conjugate targeting the development of antibody-drug conjugates (ADCs). It plays a crucial role in synthesizing ADCs, specifically REGN5093-M114, leveraging its mechanism of action for selective cytotoxicity in targeted cancer therapies. This compound is essential for researchers focused on enhancing therapeutic efficacy while minimizing off-target effects in oncology applications. -
ADC Linker
MC-VC-PAB-Tubulysin M is a synthetic antibody-drug conjugate (ADC) linker that combines the potent tubulin polymerization inhibitor, Tubulysin M, with the cleavable linker MC-vc-PAB. This conjugate targets and disrupts microtubule dynamics, offering potential for selective cytotoxicity in cancer treatment. It is primarily utilized in the development of ADCs to enhance therapeutic efficacy while minimizing off-target effects in various cancer research applications. -
Drug-Linker Conjugates for ADC
AMCC-DM1 is a drug-linker conjugate featuring the potent tubulin inhibitor DM4 and the non-cleavable linker AMCC. This compound is designed for use in antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutic agents to cancer cells. Its unique structure allows for sustained cytotoxicity while minimizing off-target effects, making AMCC-DM1 a valuable tool for research in cancer therapeutics and ADC development.
